Chief of Neuro-oncology in the Department of Neurology
Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Chicago, Illinois, United States
Dr. Roger Stupp is an internationally recognized medical oncologist with a special focus on innovative cancer treatments and drug development, notably for brain tumors and brain metastases. At Northwestern, he is leading the Division of Neuro-Oncology, and serving as the Co-Director of the Malnati Brain Tumor Institute and Associate Director for the Lurie Comprehensive Cancer Center.
Dr. Stupp has been the lead investigator for numerous clinical trials from first-in-human phase 1 to pivotal phase 3 registration studies. In the brain tumor field, he is best known for his contributions of temozolomide (Temodar®) and radiation in the first line treatment of brain tumors (the “stupp protocol”), and establishing MGMT as a predictive marker for benefit from alkylating agent chemotherapy. He was also the lead investigator establishing Tumor Treating Fields (Optune®) as an innovative treatment modality. Two novel treatments that based on his research received FDA approval and are today standard of care for patients suffering from glioblastoma.
Progress in brain tumors treatment have been lagging other cancers for a variety of reasons. The brain is physiologically surrounded by a special barrier that protect it from toxins and damage, however, often also protects tumor cells from medical treatment. We are investigating innovative strategies to open the blood-brain barrier selectively, temporarily, and reversibly, thus facilitate novel medicines (including immunotherapy) to reach tumor in higher concentrations. When treating brain tumors and developing novel treatments, early evaluation of treatment response it of utmost importance and allows to rapidly adapt treatment strategy as needed. Cutting edge imaging technology paired with specialized expertise are available to accurately evaluate tumor growth and tumor response. Numerous clinical trials led by Dr. Stupp and his colleagues provide access to cutting edge brain tumor treatments and care.
Disclosure information not submitted.
Sunday, May 5, 2024
3:33 PM – 3:35 PM CT